Working… Menu

Phase IV Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat Growth Hormone Deficiency Children

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02314676
Recruitment Status : Unknown
Verified December 2014 by GeneScience Pharmaceuticals Co., Ltd..
Recruitment status was:  Recruiting
First Posted : December 11, 2014
Last Update Posted : December 11, 2014
Information provided by (Responsible Party):
GeneScience Pharmaceuticals Co., Ltd.

Brief Summary:
This study evaluates the safety and efficiency of Pegylated Somatropin (PEG Somatropin) Injection in the treatment of endogenous growth hormone deficiency (GHD) in the broad population of children. Half of participants will receive the high dose, while the other half will receive the low dose.

Condition or disease Intervention/treatment Phase
Dwarfism, Pituitary Biological: PEG-somatropin Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 900 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Study Start Date : November 2014
Estimated Primary Completion Date : July 2017

Arm Intervention/treatment
Experimental: PEG-somatropin Biological: PEG-somatropin

Primary Outcome Measures :
  1. Actual height of the patient after treatment compared with the mean height of the population and the standard deviation (SD) of the height of the population for that chronological age [ Time Frame: 26 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   3 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Before starting treatment, according to the medical history, clinical symptoms and signs, GH stimulation test and imaging examination, patients are diagnosed as GHD.
  • According to the height statistical data of Chinese children's physique development in nine cities in 2005, height is lower than the third percentile of growth curve of normal children with the same age and gender.
  • Height velocity (HV) ≤5.0 cm/yr.
  • GH stimulation test with two different mechanisms affirms that GH peak concentration of patients' plasma <10.0ng/ml.
  • Bone age (BA) ≤9 years in girls and ≤10 years in boys, at least 1 year less than his/her chronological age (CA).
  • Be in preadolescence (Tanner stage 1) and have a CA ≧ 3 years.
  • Receive no prior GH treatment within 6 months.
  • Sign informed consent.

Exclusion Criteria:

  • People with abnormal liver or kidney function (ALT> 2 times the upper limit of normal value, Cr> the upper limit of normal value).
  • Patients positive for hepatitis B core antigen (HBc), hepatitis B surface antigen (HBsAg) or hepatitis B e antigen (HBeAg).
  • People with known highly allergic constitution or allergy to the drug of the study.
  • People with severe cardiopulmonary, hematological and malignant tumors diseases or general infection and immune deficiency.
  • Potential tumor patients (family history).
  • Diabetic.
  • Abnormal growth and development, such as Turner syndrome, constitutional delay of growth and puberty, Laron syndrome, growth hormone receptor deficiency, girls of growth retardation without excluding abnormal chromosome.
  • Subjects took part in other clinical trial study within 3 months.
  • Other conditions which in the opinion of the investigator preclude enrollment into the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02314676

Layout table for location contacts
Contact: Junfen Fu, Ph.D 13777457849

Layout table for location information
China, Anhui
First People's Hospital of Wuhu Recruiting
Wuhu, Anhui, China
Contact: Jiayan Pan         
China, Zhejiang
Children's Hospital Affiliated to Zhejiang University Recruiting
Hangzhou, Zhejiang, China
Contact: Junfen Fu, Ph.D    13777457849   
Sponsors and Collaborators
GeneScience Pharmaceuticals Co., Ltd.
Layout table for investigator information
Principal Investigator: Junfen Fu, Ph.D Children's Hospital Affiliated to Medical College of Zhejiang University
Layout table for additonal information
Responsible Party: GeneScience Pharmaceuticals Co., Ltd. Identifier: NCT02314676    
Other Study ID Numbers: GenSci 004 CT
First Posted: December 11, 2014    Key Record Dates
Last Update Posted: December 11, 2014
Last Verified: December 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Dwarfism, Pituitary
Pituitary Diseases
Hypothalamic Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Endocrine System Diseases
Bone Diseases, Developmental
Bone Diseases
Musculoskeletal Diseases
Genetic Diseases, Inborn
Bone Diseases, Endocrine